• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

News

Transgene codon usage drives viral fitness and therapeutic efficacy in oncolytic adenoviruses

28 de July de 2021
NAR Cancer. 2021 Apr 26;3(2):zcab015. doi: 10.1093/narcan/zcab015.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2021-07-28 10:00:002021-07-28 10:00:00Transgene codon usage drives viral fitness and therapeutic efficacy in oncolytic adenoviruses

Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

28 de July de 2021
J Natl Cancer Inst. 2022 Jan 11;114(1):109-122. doi: 10.1093/jnci/djab147.ABSTRACTBACKGROUND:…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-07-28 10:00:002021-07-28 10:00:00Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

Heterogeneity and Cancer-Related Features in Lymphangioleiomyomatosis Cells and Tissue

27 de July de 2021
Mol Cancer Res. 2021 Nov;19(11):1840-1853. doi: 10.1158/1541-7786.MCR-21-0220.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-07-27 10:00:002021-07-27 10:00:00Heterogeneity and Cancer-Related Features in Lymphangioleiomyomatosis Cells and Tissue

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

15 de July de 2021
Nat Commun. 2021 Jul 14;12(1):4319. doi: 10.1038/s41467-021-24618-3.ABSTRACTDespite…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2021-07-15 10:00:002021-07-15 10:00:00SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

15 de July de 2021
Nat Commun. 2021 Jul 14;12(1):4319. doi: 10.1038/s41467-021-24618-3.ABSTRACTDespite…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-07-15 10:00:002021-07-15 10:00:00SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

Lung Cancer Management with Silibinin: A Historical and Translational Perspective

2 de July de 2021
Pharmaceuticals (Basel). 2021 Jun 11;14(6):559. doi: 10.3390/ph14060559.ABSTRACTThe…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-07-02 10:00:002021-07-02 10:00:00Lung Cancer Management with Silibinin: A Historical and Translational Perspective

Ubiquitin ligase RNF8 suppresses Notch signaling to regulate mammary development and tumorigenesis

1 de July de 2021
J Clin Invest. 2021 Jul 1;131(13):e152424. doi: 10.1172/JCI152424.NO…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-07-01 10:00:002021-07-01 10:00:00Ubiquitin ligase RNF8 suppresses Notch signaling to regulate mammary development and tumorigenesis

Bivalent chromatin as a therapeutic target in cancer: An in silico predictive approach for combining epigenetic drugs

21 de June de 2021
PLoS Comput Biol. 2021 Jun 21;17(6):e1008408. doi: 10.1371/journal.pcbi.1008408.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-06-21 10:00:002021-06-21 10:00:00Bivalent chromatin as a therapeutic target in cancer: An in silico predictive approach for combining epigenetic drugs

Combination of chemotherapy with BRAF inhibitors results in effective eradication of malignant melanoma by preventing ATM-dependent DNA repair

18 de June de 2021
Oncogene. 2021 Aug;40(31):5042-5048. doi: 10.1038/s41388-021-01879-2.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2021-06-18 10:00:002021-06-18 10:00:00Combination of chemotherapy with BRAF inhibitors results in effective eradication of malignant melanoma by preventing ATM-dependent DNA repair

KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer

8 de June de 2021
Future Oncol. 2021 Sep;17(25):3291-3299. doi: 10.2217/fon-2020-1133.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2021-06-08 10:00:002021-06-08 10:00:00KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer

Germinal epimutation of Fragile Histidine Triad (FHIT) gene is associated with progression to acute and chronic adult T-cell leukemia diseases

7 de June de 2021
Mol Cancer. 2021 Jun 6;20(1):86. doi: 10.1186/s12943-021-01370-2.ABSTRACTBACKGROUND:…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-06-07 10:00:002021-06-07 10:00:00Germinal epimutation of Fragile Histidine Triad (FHIT) gene is associated with progression to acute and chronic adult T-cell leukemia diseases

Evolution of kinase polypharmacology across HSP90 drug discovery

2 de June de 2021
Cell Chem Biol. 2021 Oct 21;28(10):1433-1445.e3. doi: 10.1016/j.chembiol.2021.05.004.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-06-02 10:00:002021-06-02 10:00:00Evolution of kinase polypharmacology across HSP90 drug discovery
Page 38 of 87«‹3637383940›»

Filter by categories

  • Alemany’s & Piulats’s lab (133)
  • Antolin's lab (36)
  • Aytes's Lab (25)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (110)
  • Sin categoría (5)
  • Sureda's & Farre's Lab (312)
  • Viñals's lab (111)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}